Zymeworks (ZYME) Net Equity Issued and Repurchased (2022 - 2023)
Zymeworks (ZYME) reported Net Equity Issued and Repurchased of $26.2 million for Q2 2023, up 14203.76% on a YoY basis from N/an in Q2 2022, and up 14203.76% sequentially from -$186000.0 in Q2 2022.
Zymeworks (ZYME) Net Equity Issued and Repurchased (2022 - 2023) Analysis & Trends
Zymeworks (ZYME) has 2 years of Net Equity Issued and Repurchased data on file, last reported at $26.2 million in Q2 2023.
- For the quarter ending Q2 2023, Net Equity Issued and Repurchased rose 14203.76% year-over-year to $26.2 million; the trailing twelve-month figure through Sep 2024 stood at $26.2 million (changed 0.0% YoY), and the FY2023 full-year result was $26.2 million, down 75.6% from the prior year.
- Net Equity Issued and Repurchased climbed to $26.2 million in Q2 2023, from -$186000.0 in the prior quarter.
- In the past five years, Net Equity Issued and Repurchased ranged from a high of $107.7 million in Q1 2022 to a low of -$186000.0 in Q2 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 163.10 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 141.90 Mn |
| 10 | Zymeworks | 1.73 Bn | 1.36 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 26.23 Mn |
| Jun 30, 2023 | 26.23 Mn |
| Jun 30, 2022 | -186,000.00 |
| Jun 30, 2022 | -186,000.00 |
| Mar 31, 2022 | 107.72 Mn |
| Mar 31, 2022 | 107.72 Mn |